Showing 2941-2950 of 3039 results for "".
- Sangamo Announces Completion of TxCell Acquisitionhttps://modernod.com/news/sangamo-announces-completion-of-txcell-acquisition/2476169/Sangamo Therapeutics announced the completion of the acquisition of TxCell, which is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of
- First Patient Successfully Implanted with Implandata’s Eye Pressure Sensor for Continual Glaucoma Monitoringhttps://modernod.com/news/first-patient-successfully-implanted-with-implandatas-eye-pressure-sensor-for-continual-glaucoma-monitoring/2476170/Ophthalmic medical device company Implandata Ophthalmic Products announced that the first patient in its international, multicenter, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the supr
- Alcon Outlines Growth Strategy as Spinoff Nearshttps://modernod.com/news/alcon-outlines-growth-strategy-as-spinoff-nears/2479633/With its proposed spinoff from Novartis just months away, Alcon executives said they will focus on an aging population and the myopia epidemic to drive growth. Alcon executives
- Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usabilityhttps://modernod.com/news/eyenovia-publishes-pg21-phase-2-trial-results-examining-iop-lowering-effect-and-patient-usability/2479637/Eyenovia announced that the full results of its phase 2 PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-
- Gene Therapy Luxturna Approved in EU to Restore Vision in People With Rare Inherited Retinal Diseasehttps://modernod.com/news/gene-therapy-luxturna-approved-in-eu-to-restore-vision-in-people-with-rare-inherited-retinal-disease/2479651/Novartis announced that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene and who have enough viable retinal cells. The authorization is valid in all 28 member st
- Georgia Eye Associates Affiliates with EyeSouth Partnershttps://modernod.com/news/georgia-eye-associates-affiliates-with-eyesouth-partners/2479657/EyeSouth Partners has announced that it has completed a strategic partnership with Georgia Eye Associates, expanding its presence into the Lawrenceville and northeast Atlanta regions. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower
- Envision Research Institute Announces Search for Post Doctoral Fellows to Study Low Visionhttps://modernod.com/news/envision-research-institute-announces-search-for-post-doctoral-fellows-to-study-low-vision/2479664/The Gigi & Carl Allen Envision Research Institute (ERI) is now calling for letters of intent to apply for its next round of postdoctoral research fellowships. Launched in 2015 with a goal to restore function to those who are blind and visually impaired, the ERI provides access to funds, facil
- American Academy of Optometry Announces Barbara Caffery, OD, PhD, FAAO, as Presidenthttps://modernod.com/news/american-academy-of-optometry-names-barbara-caffery-od-phd-faao-as-president/2479665/The American Academy of Optometry has named Barbara Caffery, OD, PhD, FAAO, the incoming President of the American Academy of Optometry. Dr. Caffery was formally inducted during the Academy’s annual meeting in San Antonio, Texas on November 10, 2018. She is the first Canadian woman to serve as pr
- New Melanoma Treatments Do Not Supplant Surgery as First-Line Therapyhttps://modernod.com/news/new-melanoma-treatments-do-not-supplant-surgery-as-first-line-therapy/2479670/Although several new melanoma treatments have shown promise, none replaces surgery as the primary therapy yet, according to updated guidelines from the American Academy of Dermatology (AAD), as reported in Reuters Health. “Su
- Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Diseasehttps://modernod.com/news/acucela-initiates-phase-3-study-of-emixustat-addressing-patients-with-stargardt-disease/2479674/Acucela announced that on November 7, 2018, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (emixustat), in subjects with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, a